<DOC>
	<DOCNO>NCT00501722</DOCNO>
	<brief_summary>The primary objective determine optimal dose range dose SR121463B treatment ascites correction hyponatraemia use concomitantly standard dose regimen spironolactone . The secondary objective determine tolerability different fix dos SR121463B 14 day treatment period cirrhotic ascites . This Hypo~CAT study follow single-blind , placebo-controlled , one-year long-term safety extension ( Expo~CAT ) . The first extension follow another long-term study ( PASCCAL-1 ) .</brief_summary>
	<brief_title>Satavaptan Dose-Ranging Study Hyponatraemic Patients With Cirrhotic Ascites</brief_title>
	<detailed_description />
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Ascites</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Satavaptan</mesh_term>
	<criteria>Cirrhosis liver confirm ultrasound , endoscopic examination , biochemical evidence Moderate tense ascites Patients hyponatremia , define serum sodium concentration â‰¤130 mmol/L The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>cirrhotic ascites</keyword>
	<keyword>hyponatraemia</keyword>
</DOC>